Published in OnDrug Delivery, Bill Welch, Executive Director, Market Development of PCI Pharma Services explores how early development selections, structured timelines and adoption of a “path of least resistance” can reduce technical, regulatory and commercial risk, thereby optimizing product commercialization.
View PDF to read the full whitepaper.